• Français
    • English
  • Français 
    • Français
    • English
  • Login
View Document 
  •   Savoirs UdeS Home
  • Médecine et sciences de la santé
  • Publications et recherches – Médecine et sciences de la santé
  • Médecine et sciences de la santé – Articles de périodiques
  • View Document
  •   Savoirs UdeS Home
  • Médecine et sciences de la santé
  • Publications et recherches – Médecine et sciences de la santé
  • Médecine et sciences de la santé – Articles de périodiques
  • View Document
JavaScript is disabled for your browser. Some features of this site may not work without it.

Browse

All of Savoirs UdeSDomains & CollectionsBy Issue DateAuthorsTitlesSubjectsDirectorsThis CollectionBy Issue DateAuthorsTitlesSubjectsDirectors

My Account

Login

Statistics

View Usage Statistics

Randomized placebo-controlled cross-over designs in clinical trials : a gold-standard to be reassessed

Thumbnail
View/Open
Article de périodique (294.0Kb)
Publication date
2012
Author(s)
Léonard, Guillaume; Lafrenaye, Sylvie; Goffaux, Philippe
Editor(s)
Université de Sherbrooke. École de réadaptation
Université de Sherbrooke. Département de pédiatrie
Université de Sherbrooke. Département de chirurgie
Subject
Bias
 
Cross-over studies
 
Placebo effect
 
Placebos/administration and dosage
 
Randomized controlled trials as topic/methods
 
Research design
 
Transcranial magnetic stimulation/adverse effects
Show full document record
Abstract
Placebo effects are well-known phenomena in medicine and biology. In fact, placebos are used as control conditions in randomized cross-over clinical trials to validate new treatments. Only recently, however, has it become apparent that the conditioning and/or expectation effects provided by the experience of placebos can influence the results of clinical trials. It seems that combining shams and sequences has prejudiced the conclusions provided by cross-over designs. Frighteningly, this bias is always in the same direction, namely to increase the risk of rejecting potentially valid treatments. New models for clinical trials should be encouraged if we wish to market new and truly valid treatments.
URI
http://hdl.handle.net/11143/10141
Collection
  • Médecine et sciences de la santé – Articles de périodiques [276]

DSpace software [version 5.4 XMLUI], copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback
 

 


DSpace software [version 5.4 XMLUI], copyright © 2002-2015  DuraSpace
Contact Us | Send Feedback